Komori
Sawai Group Holdings (4887) · InitiativeFirst statedLatest Earnings (2026-08-10): "Achieved"

Expanding the Cardiovascular Product Portfolio Through the Transfer of Warfarin Rights

First written in FY2025. 1 of 3 entries say "Restated". Latest entry: 2026-08-10.

3entries
2years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2025 – 2026-05-152025: 120252026: 22026
Same theme, other companies
Expanding the Cardiovascular Product Lineup Through the Transfer of Rights to WarfarinA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  2. FY2025First statedAnnual report

    「また、2025年３月には日本市場における経口抗凝固剤「ワーファリン」の権利をエーザイ株式会社から承継する契約を締結しました。循環器領域の製品ラインアップを拡充することで、当社ジェネリック医薬品とのシナジー効果を期待しております。」

    2025年3月にワーファリンの日本市場における権利承継契約を締結し、循環器領域の製品ラインアップ拡充と既存ジェネリック医薬品とのシナジーを位置づけた。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sawai Group Holdings yet. It last moved in the Earnings of 2026-08-10: "Achieved".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.